# MRD-negative complete remission

Source: https://onco.cc/terms/mrd-negative-cr/  
OnCo record `mrd-negative-cr` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MRD-negative complete remission means not just no leukaemia visible under the microscope, but none detectable with tests a thousand times more sensitive. It is the goal of modern leukaemia treatment.

## Summary

Complete remission with undetectable measurable residual disease by flow (10^-4) or molecular methods (10^-5 to 10^-6). Prognostic across AML, ALL, CLL, and myeloma; accepted as a regulatory endpoint in ALL (blinatumomab MRD+ label) and, since FDA ODAC 2024, as an accelerated-approval endpoint in myeloma. Drives transplant decisions (AML), blinatumomab consolidation (ALL), and duration debates (CLL).

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Minimal_residual_disease
- Heuser et al., 2021 update on MRD in acute myeloid leukaemia: ELN MRD Working Party consensus (Blood 2021): https://doi.org/10.1182/blood.2021013626

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multiparameter flow cytometry MRD](https://onco.cc/technologies/flow-cytometry-mrd/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- key papers: [2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party](https://onco.cc/key-papers/paper-heuser-blood/), [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL](https://onco.cc/key-papers/paper-maude-ctl019-all-nejm-2014/), [VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy](https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/)
- targets: [NPM1 mutation](https://onco.cc/targets/npm1/)
- trials: [CAPTIVATE](https://onco.cc/trials/captivate/), [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/), [CLL14](https://onco.cc/trials/cll14/), [ECOG-ACRIN E1910](https://onco.cc/trials/e1910/), [myeloMATCH](https://onco.cc/trials/myelomatch/), [PhALLCON](https://onco.cc/trials/phallcon/)
- ideas: [MRD-guided transplant decisions in intermediate-risk AML](https://onco.cc/ideas/idea-mrd-guided-transplant-aml/), [MRD-guided treatment duration in CLL](https://onco.cc/ideas/idea-mrd-guided-stop-cll/), [Transplant-free Ph-positive ALL for MRD-negative adults](https://onco.cc/ideas/idea-transplant-free-ph-all/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/)

---
JSON: https://onco.cc/api/v1/entities/mrd-negative-cr.json